U.S. Markets open in 5 hrs 26 mins

Apricus Biosciences, Inc. (APRI)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.04+0.01 (+0.97%)
At close: 4:00PM EDT
People also watch
BIOCETRMANTHPULMCPRX
  • Next up...another reverse split....watch your shares go away....
  • Next earning lost .27 cents.
    Good luck.
  • Volume and upward price today
  • whats going on with this stock. is this a buy ahead of earnings?
  • RALLYYYYYYYYYYYYYYYYYYY
    BIG DEAL TO ACQUIRE UP TO 9 MARKETED PRODUCTS IMMINENT = 20 BAGGER POTENTIAL !!!
    AQSZF (MC $11 M) is close to profitability and to file 3 NDA and the whole company is valued at ridiculous $11 Million ,this unknown stock is definitely one of the cheapest Biotech in the sector .Stock should be at minimum $2+ right now .

    Market Cap :US$ 11 Million
    Cash $4.1 Million << enough untill mid 2018
    Price 0.18

    MUST WATCH to realize the MONSTER POTENTIAL HERE
    https://www.dukascopy.com/tv/en/view/204408#00

    Presentation
    http://www.aequuspharma.ca/Investors/AQS%20investor%20November%202016_web.pdf

    Operational profitability estimated in 2017

    File for CDN approval of Topiramate XR in 1H 2017

    File for CDN approval of Oxcarbazepine XR in 1H 2017

    Additional Product Deals in 2017

    Partnership for AQS1301 in 2017

    Two products launches to date (Tacrolimus IR and Vistitan™)

    3 long-acting, transdermal programs in development, on track to file NDA in 2018

  • I'm certain the share price will come back up. I think this was a sell on news sort of situation. I imagine it being around 1.40 next week eventually
  • welp... it wasn't a beat. but at least you guys didn't lose. soooo, congrats!
  • Today is the day!
  • Cancer is everywhere! Chemo is a $100 Billion dollar industry and one tiny little company threatens to replace it with a product that appear to really work well and even with very minimal side effects. In fact, at the end of a phase III ten year brain cancer trial where the average patient with chemo lives only 14 months, this new immune therapy has been responsible for more than 100 BRAIN CANCER PATIENTS STILL LIVING AFTER TEN YEARS. OVER 100!

    Fortunate investors will discover this tiny company before final phase III results are released soon.
    https://www.nwbio.com

    Home - Northwest Biotherapeutics
    www.nwbio.com
  • Keep going dowm,Im out.
    Before to late.
  • in APRIs latest 10k over $300M was invested to date in developing Vitaros....so a fair sale to Ferring would be $120M with royalties for all outside U.S. rights. Not a weak $11M with no royalties? what on Earth is wrong with pascoe? This smacks of desperation, imo. putting him on par with Vivian Lui ex CEO of NEXM who sold all U.S. Vitaros rights to Warner Chilcott for $2m.... fact....
    On March 8, 2017 , the Company entered into an asset purchase agreement (the “Ferring Asset Purchase Agreement”) with Ferring International Center S.A. (“Ferring’), pursuant to which it sold to Ferring its assets and rights related to Vitaros outside of the United States for approximately $11.5 million . In addition to the upfront payment, Ferring paid the Company approximately $0.7 million for the delivery of certain product-related inventory. The Company is also eligible to receive two additional quarterly payments totaling $0.5 million related to transition services, subject to certain limitations. The Company has retained the U.S. development and commercialization rights for Vitaros, which the Company has in-licensed from Allergan. The Company used approximately $6.6 million of the proceeds from the sale to repay all outstanding amounts due and owed, including applicable termination fees, under its Loan and Security Agreement (the “Credit Facility”) with Oxford Finance LLC (“Oxford”) and Silicon Valley Bank (“SVB”) (Oxford and SVB are referred to together as the “Lenders”).
  • According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $1.24

    According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $1.24
  • http://www.cnbc.com/2017/05/15/us-markets.html

    Nasdaq hits record high as tech stocks rise; oil prices jump 3%
    The Nasdaq composite hit a fresh record high on Monday as gains in large-cap tech stocks lifted the index.
    www.cnbc.com
  • Shorts one day to cover.
  • The chart looks good as well.
  • This was such a hype.
  • Anyone here remember the DIVERSION tactics of Pascoe? imo, When we were crying why he was giving us Abbott Canada launch dates that were non existent.. so what does he do to thro us off? ..he brought in the CEO of Majorelle Pharmacuticals who just signed into market Vitaros in France. And how they both were telling us what a huge market France would be having recently seen $17M alone in a year, alone, in just MUSE sales........
    now a few years later pascoe sells all Europe and all outside U.S. Vitaros sales for a measly $12M does anyone here beside me see this needs to be reported to the SEC? It is the complete opposite of what he and the rest of them have been telling us about Europe Vitaros sales how they are doubling etc etc....for year and we were lied to?
  • Wondering what will today bring us
  • We need $3
  • considering this compnay going back to NEXM has spent to date over $300M developing Vitaros, answer me this: why would the CEO sell all outside Vitaros sales fro a measly $12M? that is equivalent to Vivian Lui selling all U.S. rights for $2m......decisions bordering on insanity, imo, who cares about NASD delisting at what cost giving up your revenue stream of outside U.S. Vitaros sales? is the $12M more important then the growing $10M a year in Vitaros revenues per year? is his salary and perks worth stripping this company of its only revenue source?